INFANRIX IPV HIB

This brand name is authorized in Austria, Cyprus, Estonia, Hong Kong, Croatia, Lithuania, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom

Active ingredients

The drug INFANRIX IPV HIB contains a combination of these active pharmaceutical ingredients (APIs):

1 Diphtheria toxoid UNII 3U7E3O07S8 - CORYNEBACTERIUM DIPHTHERIAE

Read about Diphtheria toxoid

2 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

3 Pertussis toxoid

Read about Pertussis toxoid

4 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

5 Pertactin (69-kDa outer membrane protein-69K) UNII 2QNL82089R - BORDETELLA PERTUSSIS

Read about Pertactin

6 Inactivated poliovirus vaccine type I UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

7 Inactivated poliovirus vaccine type II UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

8 Inactivated poliovirus vaccine type III UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

9 Haemophilus influenzae B UNII FLV5I5W26R - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 1482 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN

Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. Read about Haemophilus influenzae B

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA06	Diphtheria-Haemophilus influenzae B-pertussis-poliomyelitis-tetanus	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1043851
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 107766
Country: HK	Department of Health Drug Office	Identifier(s): 47367
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-255493749
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1006003
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 8484
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100194053
Country: SG	Health Sciences Authority	Identifier(s): 10988P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 7063101
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699522967421